Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 trial of isaralgagene civaparvovec(ST-920) for the treatment of Fabry disease

Next Previous
X
Search
Trial Profile

A Phase 3 trial of isaralgagene civaparvovec(ST-920) for the treatment of Fabry disease

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Isaralgagene civaparvovec (Primary)
  • Indications Fabry's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Sangamo Therapeutics

    • Most Recent Events

    • 08 Aug 2023 According to a Sangamo Therapeutics media release, the company has received productive written feedback from U.S. FDA on proposed Phase 3 trial strategy. The company is Requesting specific additional clarifications before submitting a proposed phase 3 protocol to the FDA, which is expected to be as early as the end of 2023.
    • 26 Apr 2023 According to a Sangamo Therapeutics media release, company plans to meet with the FDA to advance the designing of this study in the summer.
    • 22 Feb 2023 According to a Sangamo Therapeutics media release, trial start anticipated by the end of 2023, depending on regulatory interactions. Dosing of the first patient in the trial could begin as early as the first part of 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top